) recently completed patient enrollment for the international,
randomized study - SERVE-HF. The study will be conducted on 1,325
participants to assess whether treatment of central
sleep-disordered breathing (central sleep apnea) can improve
survival and outcomes of patients with stable heart failure.
ALERE INC (ALR): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis
LEMAITRE VASCLR (LMAT): Free Stock Analysis
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
SERVE-HF is being carried out in over 80 sites across the globe.
These sites are located in Germany, Norway, Sweden, Denmark,
Switzerland, Finland, France, the U.K., the Netherlands, the
Czech Republic and Australia.
SERVE-HF commenced in 2008 to establish the health impact of the
adequate treatment of central sleep-disordered breathing on
mortality and morbidity in heart failure patients. The study is
expected to round off by mid-2015. ResMed expects the results in
the first half of 2016.
SERVE-HF will mainly establish whether controlling central sleep
apnea in patients with Cheyne-Stokes respiration (CSA-CSR)
through ResMed's PaceWave proprietary Minute Ventilation ASV
technology (found in the company's AutoSet CS and VPAP Adapt
devices) will lead to higher survival rates and reduce
hospitalizations in the patient population.
According to findings, roughly 14 million Europeans suffer from
heart failure. Additionally, in these patients, central
sleep-disordered breathing is highly prevalent co-morbidity.
Articles published in medical journals like
European Journal of Heart Failure
Archives of Cardiovascular Disease
reveal that approximately 30%-50% of heart patients are highly
prone to this co-morbid condition.
Given this backdrop, the outcome of the SERVE-HF study will have
crucial impact on the treatment of these co-morbid conditions. A
health economics analysis will further determine the potential
economic gains from ResMed's technology to treat CSA-CSR.
ResMed currently holds a major position in the worldwide market
for generators, masks, and related accessories for the treatment
of sleep-disordered breathing. Favorable outcomes from this
breakthrough clinical study that demonstrate the clinical
efficacy of ResMed's AutoSet CS and VPAP Adapt devices will be a
major boost for the company.
Considering the market overview, there is massive growth
opportunity driven by lifestyle trends, further penetration and
increasing awareness. Currently, ResMed carries a Zacks Rank #3
While we remain on the sidelines for ResMed, other medical sector
Boston Scientific Corporation
LeMaitre Vascular, Inc.
) are worth considering. Alere carries a Zacks Rank #1 (Strong
Buy) whereas the other two are Zacks Rank #2 (Buy) stocks.